DePuy Synthes Sales Inc.
$2.4M 35,060 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Saluda Medical Americas, Inc.
Saluda Medical Americas, Inc. reported $2,442,347.85 across General Payments, Research, and Ownership to 11,524 physicians and teaching hospitals across 11,687 transactions.
- $2.4M Top quartile payer
- All-tracks total
- 11,687 Top 10% volume
- Transactions
- 11,524 Top 10% reach
- Recipients
- +$99.9K
- General Payments vs PY2023
Saluda Medical Americas, Inc. reported $2,442,347.85 across all CMS Open Payments tracks (General + Research + Ownership) to 11,524 physicians and teaching hospitals in Program Year 2024 - ranking #409 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,828,284.81, averaging $211.94 per recipient.
How Saluda Medical Americas, Inc.'s $2.4M all-tracks total breaks down
Saluda Medical Americas, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
66/100
Total payments
F
33/100
Transaction volume
A
95/100
Physician reach
A
97/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer saluda-medical-americas-inc Saluda Medical Americas, Inc.
$2.4M · #409/1,925 · 0.0% industry · PY2024
- TOT $2.4M
- RANK #409
- SHARE 0.0%
- TXN 11,687
- RCP 11,524
- CAT 3
- GEN $1.8M
- ΔGEN +$99.9K
- TOP1 11.7%
- PY 2024
Volume peers
Nearest volume peer: DePuy Synthes Sales Inc. ($2.4M)
Saluda Medical Americas, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Saluda Medical Americas, Inc.'s CMS-reported General Payments increased by $99.9K (+5.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SALUDA MEDICAL AMERICAS, INC.PY2023: SALUDA MEDICAL AMERICAS, INC.PY2024: Saluda Medical Americas, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,728,431.40
- PY2024
- $1,828,284.81
What the Data Shows for Saluda Medical Americas, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Saluda Medical Americas, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $1.1M, accounting for 58.4% of this company's General Payments and 337 transactions.
General Payment Breakdown by Type
Saluda Medical Americas, Inc. made 3 types of general payments. "Consulting Fee" is the largest category at $1.1M, 58.4% of General Payments.
How Saluda Medical Americas, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.1M | 337 | 58.4% |
| Food and Beverage | $499.6K | 10,352 | 27.3% |
| Travel and Lodging | $261.4K | 835 | 14.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $537,263.57 (29.4%) of $1,828,284.81 in this company's General Payments records across 3,373 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Saluda Medical Americas, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Jason Pope
$214,415.28 across 133 reported transactions
- 2
Johnathan Goree
$100,060.90 across 84 reported transactions
- 3
Erika Petersen
$91,063.40 across 46 reported transactions
- 4
Nagy Mekhail
$67,445.95 across 24 reported transactions
- 5
Ajay Antony
$64,278.04 across 46 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Saluda Medical Americas, Inc. ranks #409 of 1,925 by total payments (top 21% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,478 of 1,838 by HHI (bottom 20% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Mayne Pharma Commercial LLC : $1.3M total payments, HHI 286
- IRRAS USA, Inc. : $15.1K total payments, HHI 285
- True North Surgical Inc : $27.3K total payments, HHI 281
- SK Life Science, Inc. : $2.1M total payments, HHI 281
- Stemline Therapeutics Inc. : $1.6M total payments, HHI 280
- Agiliti Health, Inc. : $1.8K total payments, HHI 278
- Saluda Medical Americas, Inc. (this company) : $1.8M total payments, HHI 278
- American Medical & Dental Supplies,Inc. : $49.7K total payments, HHI 276
- Fidia Pharma USA Inc. : $55.5K total payments, HHI 276
- Oak Med, Inc. : $9.5K total payments, HHI 275
- Ortho Dermatologics, a division of Bausch Health US, LLC : $999.3K total payments, HHI 275
- Nalu Medical, Inc. : $823.0K total payments, HHI 275
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Saluda Medical Americas, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Saluda Medical Americas, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Saluda Medical Americas, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
AstraZeneca AB
$2.5M 46 recipients
Compare payment profiles
Synthes GmbH
$2.5M 2,666 recipients
Compare payment profiles
Otsuka Pharmaceutical Co., Ltd.
$2.5M 193 recipients
Compare payment profiles
Hiossen, Inc.
$2.4M 89 recipients
Compare payment profiles
CoapTech, Inc.
$2.5M 41 recipients
Compare payment profiles
Put this to use
Saluda Medical Americas, Inc. ranks #409 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Saluda Medical Americas, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Saluda Medical Americas, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.